IRLAB Therapeutics AB, a Swedish biopharmaceutical company focused on Parkinson’s disease treatments, announced a new composition of matter patent in China for its lead drug candidate, mesdopetam. This patent covers the salt form of the drug and its manufacturing process, adding to the existing intellectual property protection already in place.
The expanded patent protection significantly bolsters the drug’s market exclusivity. IRLAB‘s CEO, Kristina Torfgard, stated that this extension could potentially keep mesdopetam protected until the mid-2040s. This extended protection is a significant value driver for the company.
Mesdopetam is designed to address levodopa-induced dyskinesias (LIDs), a debilitating side effect affecting a substantial portion of people with Parkinson’s disease. The company estimates this impacts over 1.5 million individuals across eight major global markets. The successful completion of Phase IIb trials has positioned mesdopetam for Phase III trials.
The newly granted patent complements existing substance patents already secured in key markets worldwide including the USA, Europe, and Japan. The possibility of a patent term extension could further prolong market exclusivity.
IRLAB‘s research platform, the Integrative Screening Process (ISP), has been instrumental in developing their pipeline of Parkinson’s disease treatments. Besides mesdopetam, the company is also advancing other drug candidates through various clinical trial phases. These include Pirepemat (IRL752) for fall frequency reduction and IRL757 for apathy treatment in neurodegenerative disorders. Additionally, two preclinical programs, IRL942 and IRL1117, are progressing towards Phase I studies.
IRLAB‘s origins trace back to Nobel Laureate Professor Arvid Carlsson’s research group. The company’s work is built on the fundamental understanding of the link between neurotransmitter disorders and brain diseases. The company’s commitment to innovative research and development is evident in its expanding portfolio of treatments for various stages of Parkinson’s disease. IRLAB is listed on Nasdaq Stockholm (IRLAB A).
Related
